Igc Pharma Inc IGC

$0.25 0.00 (-0.69%)

Valuation

Market cap
25,608,000
Revenue TTM
$1,271,000
Net income TTM
$-7,121,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.18

Trading

Volume
124,200
Avg volume
717,570
Day's range
$0.24 – $0.25
Shares out
103,384,000
Stochastic %K
31%
Beta
0.47
Analysts
Sell
Price target
$4.50

Price

Company profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-...

Show more

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Industry
Biotechnology
Sector
Healthcare
Phone
301 983 0998
Website
https://igcpharma.com
Address
10224 Falls Road, Potomac, United States

Latest news

Stocktwits

Shawshank_book_keeper Oct 24, 5:36 AM
$IGC he’s a placebo patient…. The drug works!!!! 💵
0 replies
RocketQueen Oct 23, 11:05 PM
$IGC Agitation and aggression in Alzheimer's disease. https://assistinghandspotomac.com/coping-with-agitation-and-aggression-in-alzheimers-disease/
0 replies
_AU79_ Oct 23, 6:51 PM
$IGC
0 replies
Reversal_Edge Oct 23, 10:13 AM
$IGC Speculative Trade: Potential bottom setup at $0.2368? Watching this level closely for a possible technical reversal 📈 🔹 Stock is testing the recent lows around $0.24 — potential support zone 🔹 Management agreed to take shares at $0.27 to settle ~$1.15M owed, rather than take cash 🔹 Recent offering at $0.30/share 🔹 Another issuance at $0.29/share and a prior transaction at $0.34/share provide additional reference points 🔹 Q4 2026 Phase 2 CALMA topline results expected for IGC-AD1, targeting agitation associated with Alzheimer’s disease Still watching — cash & dilution remain a risk, and clinical results are uncertain. But this is a level I’m watching for a potential risk/reward bounce before the Q4 catalyst. Have to let the chart confirm it first 🟡
1 replies
NewsAndFilings Oct 23, 1:05 AM
Watch Now: $VIVS, $IGC, $XXII and $SHFS Low Price Listed Stocks in Focus https://thestreetreports.com/watch-now-vivs-igc-xxii-and-shfs-low-price-listed-stocks-in-focus/
0 replies
_AU79_ Oct 23, 12:29 AM
$IGC give us phase 2 results now damn ye!
1 replies
RocketQueen Oct 22, 11:48 PM
$IGC get it...
0 replies
RocketQueen Oct 21, 1:50 PM
$IGC bought more shares this morning.
0 replies